Immunic, Inc. (NASDAQ:IMUX) Receives $7.40 Consensus Price Target from Analysts

by · The Cerbat Gem

Immunic, Inc. (NASDAQ:IMUX – Get Free Report) has been assigned an average rating of “Buy” from the eight ratings firms that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, five have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year target price among brokers that have covered the stock in the last year is $7.40.

Several equities analysts have recently issued reports on the stock. Roth Capital initiated coverage on shares of Immunic in a report on Friday, November 7th. They set a “buy” rating and a $3.00 target price for the company. HC Wainwright decreased their price objective on Immunic from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, November 14th. Chardan Capital raised Immunic to a “strong-buy” rating in a research note on Wednesday, November 19th. LADENBURG THALM/SH SH upgraded shares of Immunic to a “strong-buy” rating in a research note on Thursday, October 16th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Immunic in a research report on Monday, December 8th.

Get Our Latest Report on Immunic

Institutional Trading of Immunic

Institutional investors and hedge funds have recently modified their holdings of the stock. Qube Research & Technologies Ltd purchased a new position in shares of Immunic in the 3rd quarter valued at $29,000. Two Sigma Investments LP purchased a new stake in Immunic during the 3rd quarter valued at about $52,000. HB Wealth Management LLC purchased a new stake in shares of Immunic in the 3rd quarter valued at $81,000. Virtu Financial LLC acquired a new stake in Immunic during the 3rd quarter worth about $99,000. Finally, GSA Capital Partners LLP purchased a new position in Immunic during the third quarter valued at approximately $170,000. Institutional investors own 51.82% of the company’s stock.

Immunic Stock Down 1.3%

Shares of NASDAQ:IMUX opened at $0.61 on Friday. Immunic has a 52 week low of $0.56 and a 52 week high of $1.39. The company’s fifty day moving average is $0.75 and its 200 day moving average is $0.82. The stock has a market cap of $73.82 million, a PE ratio of -0.74 and a beta of 1.48.

Immunic (NASDAQ:IMUX – Get Free Report) last issued its earnings results on Thursday, November 13th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.05. Sell-side analysts anticipate that Immunic will post -0.94 EPS for the current year.

About Immunic

(Get Free Report)

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.

Recommended Stories